Are there any early-phase opportunities left in hepatitis C?
This article was originally published in Scrip
With Harvoni (sofosbuvir/ledipasvir; Gilead Sciences) and Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir; AbbVie) demonstrating cure rates approaching 100% in several patient subgroups, there is now a very high bar to market entry in the hepatitis C space. Pharmaceutical companies are left trying to provide incremental improvements in treatment duration and broader genotypic potency in order to differentiate newer products.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.